^
Association details:
| Biomarker: | EGFR L833V + EGFR H835L |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant (L833V/H835L) lung adenocarcinoma patient: a case report
Published date:
04/28/2023
Excerpt:
The patient admitted to our hospital for space-occupying lesions of right lower lung during an annual health checkup, and was diagnosed as stage IIIA lung adenocarcinoma. Targeted next-generation sequencing (NGS) on tumor samples showed a complex EGFR mutation: L833V/H835L in exon 21. Therefore, she was treated with osimertinib monotherapy and complete remission achieved soon.
DOI:
10.1097/CAD.0000000000001523
